FOXO4-DRI
Investigación emergenteSenolytic Peptide | p53-FOXO4 Disruptor
FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction.
Datos moleculares y de investigación
- Peso molecular
- ~4,800 Da
- Vida media
- Not established
- Rutas (investigación)
- injectable
- Almacenamiento
- Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use immediately or within short term; avoid freeze-thaw cycles
Overview
FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent ‘zombie’ cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive. The ‘DRI’ modification (D-retro-inverso) uses reversed D-amino acids to increase potency and stability. Preclinical research shows restoration of fur density, fitness, and organ function in aged mice.
Mechanism of action
FOXO4-DRI competes with FOXO4 for binding to p53, disrupting their protective interaction in senescent cells. This causes p53 to be excluded from the nucleus and triggers cell-intrinsic apoptosis (programmed cell death). Critically, this mechanism is highly selective: the FOXO4-p53 interaction is a specific vulnerability of senescent cells, while FOXO4 is minimally expressed in healthy tissues, leaving functional cells largely unharmed.
Key research findings
- Selective elimination of senescent cells
- Restoration of tissue homeostasis
- Improved fitness and physical function in aged models
- Restored fur density in aged mice
- Improved kidney function
- Alleviates chemotherapy-induced senescence
- Restores testosterone in aged males
- Reduces senescent chondrocytes in cartilage
- High selectivity spares healthy cells
Research applications
Anti-Aging
- Senescent Cell Clearance — Selectively induces apoptosis in senescent cells while sparing healthy tissue.
- Tissue Rejuvenation — Restores tissue homeostasis and function in naturally aged animal models.
- Physical Function — Improved fitness, mobility, and physical appearance in aged mice.
Organ Function
- Kidney Function — Restored renal function in aged and fast-aging mouse models.
- Testicular Function — Improved testicular microenvironment and testosterone secretion in aged mice.
- Cartilage Health — Removes senescent chondrocytes, potentially benefiting joint health.
Chemoprotection
- Chemotherapy Recovery — Neutralizes doxorubicin-induced chemotoxicity by clearing treatment-induced senescent cells.
Preguntas frecuentes sobre FOXO4-DRI
What makes FOXO4-DRI different from other anti-aging approaches?+
FOXO4-DRI is the first senolytic peptide that selectively eliminates 'zombie' senescent cells accumulating with age, whereas most anti-aging approaches target symptoms or regeneration. It disrupts FOXO4-p53 interaction in senescent cells to trigger apoptosis, effectively removing damaged cells rather than just supporting healthy ones.
Is FOXO4-DRI safe if I have a history of cancer?+
FOXO4-DRI is theoretically contraindicated in active cancer due to p53 pathway modulation, though the mechanism (disrupting FOXO4-p53 interaction) differs from therapies affecting healthy p53. Cancer history requires careful medical consideration. Most sources recommend consulting an oncologist before using, especially with active malignancy.
How much FOXO4-DRI should a human dose based on mouse studies?+
The original 2017 mouse study used 5 mg/kg IP, 3 times on alternate days. For a 60kg human, this translates to approximately 25mg per dose, administered as 3 doses every other day (75-100mg total per cycle). However, human pharmacokinetics differ significantly from mice, making these translations speculative.
What visible changes occurred in aged mice treated with FOXO4-DRI?+
Aged mice receiving FOXO4-DRI showed restored fur density, improved physical fitness, enhanced organ function (particularly kidneys), and improved testosterone levels. These dramatic improvements suggest senescent cell clearance genuinely restored tissue homeostasis, though results in humans remain theoretical.
References
- [1]Targeted Apoptosis of Senescent Cells Restores Tissue HomeostasisCell
- [2]An Example of Senolytic Self-Experimentation with FOXO4-DRIFight Aging!
- [3]FOXO4-DRI Alleviates Age-Related Testosterone Secretion InsufficiencyTheranostics
- [4]FOXO4-DRI Removes Senescent Cells from Human ChondrocytesFrontiers in Bioengineering and Biotechnology
- [5]The Disordered p53 Transactivation Domain is the Target of FOXO4-DRINature Communications
Péptidos relacionados
5-Amino-1MQ
PreclinicalNNMT Inhibitor | Longevity & Metabolic Enhancement
5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.
Adalank
Emerging researchN-Acetyl Selank Amidate | Enhanced Tuftsin Analog
Enhanced derivative of Selank with improved stability, blood-brain barrier penetration, and extended half-life compared to parent compound. Parent compound Selank approved in Russia since early 2000s.
Adamax
Emerging researchNext-Generation Semax Derivative | Nootropic Neuropeptide
Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement,
Cardiogen
Moderate researchAEDR | Cardiovascular Bioregulator Peptide
Cardiogen is a Khavinson bioregulator peptide consisting of four amino acids, derived from heart tissue research.